BHC

Bausch Health Companies Inc.

Pharmaceutical Preparations · SIC 2834CIK 885590Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$10.27B

Net Income FY2025

$0.16B

EPS (Basic, as reported)

$0.42

Net Margin FY2025

1.5%

ROE FY2025

-28.3%

Total Equity

$(0.55B)

Shares Out

374M

Business description

Bausch Health Companies Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 9,674 → 10,266 +0.7% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue9,6748,7248,3808,6018,0278,4348,1248,7579,62510,266

Cost of revenue(2,572)(2,506)————————

Selling, general & administrative(2,810)(2,582)(2,473)(2,554)(2,367)(2,624)(2,625)(2,917)(3,296)(3,438)

Total operating expenses(10,240)(8,622)(10,764)(8,804)(7,351)(7,984)(7,670)(7,794)(8,079)(8,453)

Operating income(566)102(2,384)(203)6764504549631,5461,813

Interest expense(1,836)(1,840)(1,685)(1,612)(1,534)(1,426)(1,464)(1,328)(1,388)(1,604)

Interest & investment income812111213714263348

Other income (expense), net(73)35321(1,414)(454)(373)(35)(28)(247)(142)

Pre-tax income(2,435)(1,741)(4,154)(1,837)(934)(1,024)(129)(390)167367

Income tax expense(27)(4,145)(10)(54)(375)(87)(83)(221)(239)(247)

Net income(2,408)2,404(4,144)(1,788)(560)(948)(225)(592)(46)157

EPS — basic($6.94)$6.86($11.81)($5.08)($1.58)($2.64)($0.62)($1.62)($0.13)$0.42

EPS — diluted($6.94)$6.83($11.81)($5.08)($1.58)($2.64)($0.62)($1.62)($0.13)$0.42

Shares outstanding — basic (M)347350351352355359362365368371

Shares outstanding — diluted (M)347352351352355359362365368375

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.